New Zealand HIV Therapeutics Market Analysis Report [2022-30]

New Zealand HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the New Zealand HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as TIVICAY, Body Positive, and Gilead Sciences. The market is driven by government initiatives, the prevalence of HIV infections, and awareness about HIV / AIDS. The HIV therapeutics market in New Zealand is segmented by type, product, geography, end user, and distribution channel.

ID: IN10NZPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: New Zealand AUTHOR: Dr. Vishwa Modhia

Buy Now

New Zealand HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the New Zealand HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

In the southwest Pacific Ocean, the island nation of New Zealand is made up of numerous smaller islands in addition to its two main landmasses, the North Island and the South Island. The adult prevalence of HIV/AIDS in New Zealand was less than 0.1% in 2021. According to the most recent WHO data, 10 HIV/AIDS-related deaths—or 0.04% of all deaths—occurred in New Zealand in 2020.

In New Zealand, AIDS, and HIV infection are under national surveillance by the AIDS Epidemiology Group. With an age-adjusted Death Rate of 0.18 per 100,000 people, New Zealand is ranked 148 globally. Antiretroviral drugs that are frequently prescribed in New Zealand include protease inhibitors (PIs), integrase inhibitors, fusion inhibitors, entry inhibitors, and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs, NNRTIs, and PIs). New Zealand spent 9.7% of its GDP on healthcare in 2019.

Market Dynamics

Market Growth Drivers

The treatment gap and ART coverage in New Zealand were both around 73%. In New Zealand's free market economy, prices for goods and services are established through a free market system. New Zealand participates in both the Trans-Pacific Partnership (TPP) and the Asia-Pacific Economic Cooperation (APEC).

Market Restraints

Despite the fact that New Zealand's public healthcare system typically covers ART, some people may still find it difficult to afford these medications. People might occasionally have to make co-payments or prescription charges, which add up over time.

Competitive Landscape

Key Players

TIVICAY (ViiV Healthcare group) (NZL)
Body Positive (NZL)
Gilead Sciences
ViiV Healthcare
Merck & Co.
Pfizer
AstraZeneca
Novartis
GlaxoSmithKline
Johnson & Johnson

Recent Notable Update

November 2019: New Zealand has opened the first sperm bank in the world for donors who are HIV-positive in an effort to reduce the stigma associated with the condition. Three HIV-positive men with undetectable viral loads have already expressed interest in donating. Before World Aids Day on December 1, three charities introduced perm Positive. The project's sponsors, Body Positive, the New Zealand Aids Foundation, and Positive Women Inc., hope it will inform people about HIV transmission and lessen the stigma against those who have the disease.

Healthcare Regulations and Reimbursement Policies

The Medicines and Medical Devices Safety Authority (Medsafe) is the regulatory body in charge of regulating the approval and utilization of HIV therapeutics in New Zealand. The New Zealand Ministry of Health's business unit Medsafe is in charge of overseeing the regulation of therapeutic products, such as prescription and over-the-counter medications, medical devices, and complementary medicines. Medical professionals and patients can get guidance from Medsafe on how to use therapeutic products safely. Medsafe evaluates the efficacy, quality, and safety of both new and existing products.

The Pharmaceutical Management Agency (PHARMAC), New Zealand's government-run healthcare system, typically covers the cost of antiretroviral therapy (ART) for the treatment of HIV. PHARMAC, which works to ensure that people have access to the medications they require at an affordable price, is in charge of funding the majority of prescription medicines used in New Zealand. The majority of people with HIV in New Zealand are qualified for free ART through the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.